



## Harvard Bioscience, Inc. Launches New ADMET Product

HOLLISTON, Mass., Feb. 27 /PRNewswire/ -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced the introduction of ScanTox™, a drug safety evaluation tool that provides a more sensitive means of lead optimization than currently available, as well as an in vitro alternative to the much criticized Draize irritancy test using live animals.

(Photo: <http://www.newscom.com/cgi-bin/prnh/20010227/NETU050-a>)

<http://www.newscom.com/cgi-bin/prnh/20010227/NETU050LOGO-b>)

ScanTox™ is designed to reduce the number of drug candidate "false positives" inexpensively before reaching high-cost pre-clinical and clinical trials (Phase II/III). ScanTox™ is a laser-based instrument that quantifies the relative cytotoxicity of a substance within a living and functional cultured bovine lens. With high repeatability ScanTox™ measures organ functionality of this system, and in turn can be used to measure recovery from toxic agents even at parts per million concentrations.

"We believe ScanTox™ is a breakthrough product. It perfectly fits our strategy of providing higher relevance and speed at lower cost," said David Green, President of Harvard Bioscience. "For anyone interested as well in accuracy and reproducibility, or concerned with reducing the use of live animals in research and industry, this product is a significant innovation. Like many of our products, ScanTox™ can substantially reduce product time to market. During March 26 through 28 we will be demonstrating ScanTox™ at the Society of Toxicology trade show in San Francisco and in June we will be at the Congress on In Vitro Biology meeting in St Louis."

Harvard Bioscience is a global developer, manufacturer and marketer of innovative, enabling tools in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. HBIO sells approximately 10,000 products to thousands of researchers in over 60 countries through its 1,000 page catalog, and through its distributors, the most notable of which is AP Biotech. HBIO has sales and manufacturing operations in the United States, the United Kingdom, and Germany with sales facilities in France and Canada.

Statements in this release that relate to expectations and objectives of management for future operations of Harvard Bioscience, Inc., or that otherwise relate to future performance, are forward looking statements. Actual results may differ from those projected as a result of product demand, pricing, market acceptance, economic conditions, intellectual property issues, competitive products, risks in product and technology development, and other risks identified in our Securities and Exchange Commission filings.

For information on ScanTox™, please call Derek Palmer at (508) 893- 8066. Press releases and our product catalog can be found on our web site, <http://www.harvardbioscience.com>. SOURCE Harvard Bioscience, Inc.

CONTACT: Jim Warren, CFO, [jwarren@harvardbioscience.com](mailto:jwarren@harvardbioscience.com), or David Green, President, [dgreen@harvardbioscience.com](mailto:dgreen@harvardbioscience.com), or Chane Graziano, CEO, [cgraziano@harvardbioscience.com](mailto:cgraziano@harvardbioscience.com), all of Harvard Bioscience, Inc./

### Disclaimer:

The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrences or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience's web site. For Harvard Bioscience's most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at <http://www.sec.gov>.